Increased Pontin expression is a potential predictor for outcome in sporadic colorectal carcinoma

  • Authors:
    • Johannes C. Lauscher
    • Sefer Elezkurtaj
    • Sonja Dullat
    • Sybille Lipka
    • Jörn Gröne
    • Heinz J. Buhr
    • Otmar Huber
    • Martin Kruschewski
  • View Affiliations

  • Published online on: August 10, 2012     https://doi.org/10.3892/or.2012.1968
  • Pages: 1619-1624
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Colorectal cancer is one of the leading causes of cancer-related death worldwide. Molecular biomarkers could help to predict patient outcome and to identify patients who benefit from adjuvant therapy. Pontin and Reptin are ATPases which are involved in transcriptional regulation, DNA damage repair and regulation of cell proliferation. Many interaction partners of Pontin and Reptin such as β-catenin and c-myc are important factors in carcinogenesis. We hypothesized that Pontin and Reptin expression may be a negative predictor for survival in colorectal carcinoma. Specimens from 115 patients with primary colon adenocarcinomas UICC stage III and primary rectal adenocarcinomas UICC stage II and III curatively resected at the Department of Surgery, Charité Berlin, were evaluated. Clinical follow-up data were complete and mean follow-up time of patients was 51.8 months. We evaluated the expression of Pontin, Reptin and Ki-67 by immunohistochemistry. Patients with Pontin-positive carcinomas showed no differences in recurrence-free survival (p=0.109) and overall survival (p=0.197). There were no differences in Reptin-positive carcinomas and Ki-67-positive carcinomas in recurrence-free survival (p=0.443 and p=0.160) and overall survival (p=0.477 and p=0.687). Patients with Pontin-positive colorectal carcinomas receiving adjuvant therapy had a significantly worse recurrence-free survival (p=0.008) and overall survival (p=0.011) than Pontin-negative patients with adjuvant therapy. In UICC stage III, Pontin-positive colorectal carcinomas had a significantly worse recurrence-free survival (p=0.028). Pontin-positivity seems to be a negative predictor for response to adjuvant therapy in colorectal cancer patients and may help to identify patients with adverse outcome in advanced tumor stages.
View Figures
View References

Related Articles

Journal Cover

November 2012
Volume 28 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lauscher JC, Elezkurtaj S, Dullat S, Lipka S, Gröne J, Buhr HJ, Huber O and Kruschewski M: Increased Pontin expression is a potential predictor for outcome in sporadic colorectal carcinoma. Oncol Rep 28: 1619-1624, 2012
APA
Lauscher, J.C., Elezkurtaj, S., Dullat, S., Lipka, S., Gröne, J., Buhr, H.J. ... Kruschewski, M. (2012). Increased Pontin expression is a potential predictor for outcome in sporadic colorectal carcinoma. Oncology Reports, 28, 1619-1624. https://doi.org/10.3892/or.2012.1968
MLA
Lauscher, J. C., Elezkurtaj, S., Dullat, S., Lipka, S., Gröne, J., Buhr, H. J., Huber, O., Kruschewski, M."Increased Pontin expression is a potential predictor for outcome in sporadic colorectal carcinoma". Oncology Reports 28.5 (2012): 1619-1624.
Chicago
Lauscher, J. C., Elezkurtaj, S., Dullat, S., Lipka, S., Gröne, J., Buhr, H. J., Huber, O., Kruschewski, M."Increased Pontin expression is a potential predictor for outcome in sporadic colorectal carcinoma". Oncology Reports 28, no. 5 (2012): 1619-1624. https://doi.org/10.3892/or.2012.1968